Prostate Cancer: <sup>177</sup> Lu-PSMA (Pluvicto)

177Lu-PSMA-617 (brand name Pluvicto), is a prostate-specific membrane antigen (PSMA) targeted ligand therapy. PSMA is overexpressed in most prostate adenocarcinomas and this property can be exploited therapeutically. It is prescribed for patients diagnosed with hormone-resistant metastatic prostate

Authors

Publication Details

Journal
Journal of Nuclear Medicine Technology
Published
2026-03-31
DOI
https://doi.org/10.2967/jnmt.126.272485
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prostate Cancer: 177 Lu-PSMA (Pluvicto)

Mary Beth Farrell, Eleanor Mantel, Kathy S. Thomas, Jessica Settle
Journal of Nuclear Medicine Technology
Prostate Cancer Treatment and Research
article

Prostate Cancer: 177 Lu-PSMA (Pluvicto)

Mary Beth Farrell, Eleanor Mantel, Kathy S. Thomas, Jessica Settle
article en

Abstract

177Lu-PSMA-617 (brand name Pluvicto), is a prostate-specific membrane antigen (PSMA) targeted ligand therapy. PSMA is overexpressed in most prostate adenocarcinomas and this property can be exploited therapeutically. It is prescribed for patients diagnosed with hormone-resistant metastatic prostate

Journal of Nuclear Medicine Technology
Good health and well-being
Openalex Percentile: Top 7%
Prostate Cancer Treatment and Research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.